Ritlecitinib | China | Manufacturer | Jinan Million Pharmaceutical Co., Ltd

Price	$50
Package	10g

Product Details

Product Name: Ritlecitinib	CAS No.: 1792180-81-4
EC-No.: 210-077-2	Min. Order: 10g
Purity: 99%	Supply Ability: 10KG/M
Release date: 2024/07/17

Ritlecitinib a new oral targeting inhibitor developed by Pfizer in the United States. Ritlecitinib is a medication used for the treatment of severe alopecia areata (hair loss). Ritlecitinib is a kinase inhibitor which inhibits Janus kinase 3 and tyrosine kinase. Clinical studies have proved that ritlecitinib can effectively block signaling molecules and immune cells activity, which are considered to be the cause of alopecia areata. Compared with the first generation of Pan-JAK inhibitors, the side effects are little than previous drugs because of its precise blockade. Adult and adolescent patients have better survivability on ritlecitinib. The most common side effects were headache, nasopharyngitis, and upper respiratory tract infection. But it can be well relieved after stopping the drug for a period of time. In addition, ritlecitinib is used in non-segmental vitiligo patients aged 12 years or older who are suitable for systemic treatment. This is the third clinical indication of ritlecitinib approved in China after alopecia areata and ulcerative colitis.

Company Profile Introduction

Founded in 2012, Jinan Million Pharmaceutical Co., Ltd (Jinan Milin Pharmaceutical Co., Ltd) is a modern pharmaceutical enterprise guided by innovation. Million pharm has excellent research and development capabilities and complete industrial bases with international quality management system. It is dedicated to the research, development, production and customization of pharmaceuticals and advanced pharmaceutical intermediates. Jinan Million Pharmaceutical Co., Ltd has been focusing on the research of Cerebro-cardiovascular drugs, Central nervous system drugs, Anti-cancer drugs, Anti-aging drugs, Antibacterial drugs and others for more than 10 years; the products are: Apixabn, Lurasidon, Votioxitin, Edoxabn, Loxo-292/Selpercatinib, β-nicotinamid mononucleotid, Indacaterl and their intermediates. Million has established long-term friendly cooperative relationship with customers in Egypt, Japan, India, and Russia relying on great quality and cost-competitive products. Jinan Million Pharmaceutical Co., Ltd has a 1,500㎡ R&D center in the Zhongguancun E Valley (Qihe) Incubator, equipped with complete test equipment, such as high-performance liquid chromatography, nuclear magnetic resonance spectrometer, liquid chromatography mass spectrometer, automatic polarimeter, etc., which can meet the needs of various laboratory scale tests in different conditions. The pilot workshop is equipped with 50L and 100L glass reactors, high and low temperature equipment, etc., which can support organic chemical reactions at -100°C or 200°C. In addition, Million has a production site in Linyi city with many independent production lines, such as: production line of Apixabn intermediate 20 tons/year, production line of Lurasidon intermediate 10 tons/year, which can meet the commercial production of various products. The technical team is composed of high-level talents in major of pharmacy, bio-pharmaceutical or chemical synthesis, of which 10% has doctor’s degree and 15% has mas

Recommended supplier

Product name	Price		Suppliers	Update time
1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one	$0.00/25KG	VIP5Y	Hebei Mojin Biotechnology Co., Ltd	2024-04-23
1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one	$0.00/100g		Wuhan Han Sheng New Material Technology Co.，Ltd	2023-07-10
Ritlecitinib	$0.00/100g		Wuhan Han Sheng New Material Technology Co.，Ltd	2023-07-10

Ritlecitinib NEW

Product Details

Company Profile Introduction

You may like

Recommended supplier

Jinan Million Pharmaceutical Co., Ltd